Arboleda, D.; Buitrago, C.; Vergara, E.P.; Nocua-Báez, L.C.; Saavedra, C.H.; Cortés, J.A.
Impact of Antibiotic Therapy with Ceftazidime Avibactam vs. Best Available Therapy in Adult Patients with Bacteremia Caused by Carbapenem-Resistant Enterobacterales. Antibiotics 2025, 14, 226.
https://doi.org/10.3390/antibiotics14030226
AMA Style
Arboleda D, Buitrago C, Vergara EP, Nocua-Báez LC, Saavedra CH, Cortés JA.
Impact of Antibiotic Therapy with Ceftazidime Avibactam vs. Best Available Therapy in Adult Patients with Bacteremia Caused by Carbapenem-Resistant Enterobacterales. Antibiotics. 2025; 14(3):226.
https://doi.org/10.3390/antibiotics14030226
Chicago/Turabian Style
Arboleda, Daniel, Camilo Buitrago, Erika Paola Vergara, Laura Cristina Nocua-Báez, Carlos Humberto Saavedra, and Jorge Alberto Cortés.
2025. "Impact of Antibiotic Therapy with Ceftazidime Avibactam vs. Best Available Therapy in Adult Patients with Bacteremia Caused by Carbapenem-Resistant Enterobacterales" Antibiotics 14, no. 3: 226.
https://doi.org/10.3390/antibiotics14030226
APA Style
Arboleda, D., Buitrago, C., Vergara, E. P., Nocua-Báez, L. C., Saavedra, C. H., & Cortés, J. A.
(2025). Impact of Antibiotic Therapy with Ceftazidime Avibactam vs. Best Available Therapy in Adult Patients with Bacteremia Caused by Carbapenem-Resistant Enterobacterales. Antibiotics, 14(3), 226.
https://doi.org/10.3390/antibiotics14030226
